Galantamine enhancement of long-term potentiation is mediated by calcium/calmodulin-dependent protein kinase II and protein kinase C activation

Hippocampus

Volumn 19, Issue 9, 2009, Pages 844-854

  Moriguchi, Shigeki ^a   Shioda, Norifumi ^a   Han, Feng ^a   Yeh, Jay Z ^b   Narahashi, Toshio ^b   Fukunaga, Kohji ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; CaMKII; Galantamine; LTP; NMDA; PKC

Indexed keywords

AMPA RECEPTOR; BUNGAROTOXIN RECEPTOR; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CHELERYTHRINE; CYCLIC AMP DEPENDENT PROTEIN KINASE; GALANTAMINE; MARCKS PROTEIN; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO]METHYL]PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; PHOSPHOPROTEIN DARPP 32; PHYSOSTIGMINE; PROTEIN KINASE C ALPHA; SYNAPSIN I;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME ACTIVATION; EXCITATORY POSTSYNAPTIC POTENTIAL; HIPPOCAMPUS; LEARNING DISORDER; LONG TERM POTENTIATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RECEPTOR UPREGULATION;

ANIMALS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; EXCITATORY POSTSYNAPTIC POTENTIALS; GALANTAMINE; HIPPOCAMPUS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LONG-TERM POTENTIATION; MALE; MEMBRANE PROTEINS; NEURAL PATHWAYS; NOOTROPIC AGENTS; PHOSPHORYLATION; PROTEIN KINASE C-ALPHA; RATS; RATS, WISTAR; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, NICOTINIC; SYNAPSINS;

EID: 69249155680     PISSN: 10509631     EISSN: 10981063     Source Type: Journal    
DOI: 10.1002/hipo.20572     Document Type: Article

References (41)

1. Barria A, Muller D, Derkach V, Griffith LC, Soderling TR. 1997. Regulatory phosphorylation of AMPA-type glutamate receptor by CaM-KII during long-term potentiation. Science 276:2042-2045.
2. Baxter MG, Lanthorn TH, Frink KM, Golski S, Wan R, Olton DS. 1994. D-Cycloserine, a novel cognitive enhancer, improves spatial memory in aged rats. Neurobiol Aging 15:207-213.
3. Collingridge GL, Issac JT, Wang YT. 2004. Receptor trafficking and synaptic plasticity. Nat Rev Neurosci 5:952-962.
4. 2+/calmodulin- kinase II enhances channel conductance of alpha-amino-3-hydroxy-5-methyl-4- isoxazolepropionate type glutamate receptors. Proc Natl Acad Sci USA 96:3269-3274.
5. Dysken MW, Mendels J, LeWitt P. 1992. Milacemide; a placebo-controlled study in semile dementia of the Alzheimer type. Am J Geriatric Psychiatry 40:503-506.
6. Edwards S, Simmons DL, Galindo DG, Doherty JM, Scott AM, Hughes PD, Wilcox RE. 2002. Antagonistic effects of dopaminergic signaling and ethanol on protein kinase A-mediated phosphorylation of DARPP-32 and the NR1 subunit of the NMDA receptor. Alcoholism 26:173-180.
7. Frey U, Huang YY, Kandel ER. 1993. Effects of cAMP simulate a late stage of LTP in hippocampal CA1 neurons. Science 260:1661-1664.
8. Fonnum F, Myhrer T, Paulsen RE, Wangen K, Oksengard AR. 1995. Role of glutamate and glutamate receptors in memory function and Alzheimer's disease. Ann N Y Acad Sci 757:475-486.
9. Fukunaga K, Miyamoto E. 2000. A working model of CaM Kinase II activity in hippocampal long-term potentiation and memory. Neurosci Res 38:3-17.
10. 2+/calmodulin-dependent protein kinase II in rat brain and various tissues. J Neurochem 51:1070-1078.
11. 2+/calmodulin-dependent protein kinase II and protein kinase C by glutamate in cultured rat hippocampal neurons. J Biol Chem 267:22527-22533.
12. 2+/ calmodulin-dependent protein kinase II. J Biol Chem 268:7863-7867.
13. 2+/calmodulin-dependent protein kinase II and its endgeneous substrates in the induction of long term potentiation. J Biol Chem 270:6119-6124.
14. 3H] glutamate binding. J Neurochem 48:543-551.
15. Hanndelmann GE, Nevins ME, Mueller LL, Arnolde SM, Cordi AA. 1989. Milacemide, a glycine prodrug, enhances performance of learning tasks in normal and amnestic reodents. Pharmacol Biochem Behav 34:823-828.
16. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
17. Lisman J, Schulman H, Cline H. 2002. The molecular basis of CaMKII function in synaptic and behavioral memory. Nat Rev Neurosci 3:175-190.
18. 2+/calmodulin-dependent protein kinase II and mitogen-activated protein kinase activation in hippocampal long-term potentiation. J Neurosci 19:8292-8299.
19. Maelicke A, Albuquerque EX. 2000. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Eur J Pharmacol 393:165-170.
20. Maelicke A, Samochocki M, Jostock R, Fehrenbacher A, Ludwig L, Albuquerque EX, Zerlin M. 2001. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol Psychiatry 49:279-288.
21. Morales M, Hein K, Vogel Z. 2008. Hippocampal interneurons coexpress transcripts encording the alpha-7 nicotinic receptor subunit and the cannabinoid receptor 1. Neuroscience 152:70-81.
22. Moriguchi S, Marszalec W, Zhao X, Yeh JZ, Narahashi T. 2003. Potentiation of N-methyl-D-aspartate-induced currents by the nootropic drug nefiracetam in rat cortical neurons. J Pharmacol Exp Ther 307:160-167.
23. Moriguchi S, Marszalec W, Zhao X, Yeh JZ, Narahashi T. 2004. Mechanism of action of galantamine on N-methyl-D-aspartate receptors in rat cortical neurons. J Pharmacol Exp Ther 310:933-942.
24. Moriguchi S, Shioda N, Maejima H, Zhao X, Marszalec W, Yeh JZ, Fukunaga K, Narahashi T. 2007. Nefiracetam potentiates N-methyl-D- aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor. Mol Pharmacol 71:580-587.
25. Moriguchi S, Shioda N, Han F, Narahashi T, Fukunaga K. 2008. CaM kinase II and protein kinase C activations mediate enhancement of long-term potentiation by nefiracetam in the rat hippocampal CA1 region. J Neurochem 106:1092-1103.
26. Ohmitsu M, Fukunaga K, Yamamoto H, Miyamoto E. 1999. Phosphorylation of myristoylated alanine-rich protein kinase C substrate by mitogen-activated protein kinase in cultured rat hippocampal neurons following stimulation of glutamate receptors. J Biol Chem 274:408-417.
27. Pereira EFR, Reinhardt S, Schrattenholz A, Maelicke A, Albuquerque EX. 1993. Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors in cultured hippocampal neurons. J Pharmacol Exp Ther 265:1474-1491.
28. Pereira EFR, Alkondon M, Reinhardt S, Maelicke A, Peng X, Lindstrom P, Whiting P, Albuquerque EX. 1994. Physostigmine and galanthamine: Probes for a novel binding site on the a4b2 subtypes of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells. J Pharmacol Exp Ther 270:768-778.
29. Roche KW, O'Brien RJ, Mammen AL, Bernhardt J, Huganir RL. 1996. Characterization of multiple phosphorylation sites on the AMPA receptor GluR1 subunit. Neuron 16:1179-1188.
30. Samochocki M, Hoffle A, Fehrenbacher A, Jostock R, Ludwig J, Christner C, Radina M, Zerlin M, Ullmer C, Pereira EF, Lubbert H, Albuquerque EX, Maelicke A. 2003. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 305:1024-1036.
31. Santos MD, Alkondon M, Pereira EFR, Aracava Y, Eisenberg HM, Maelicke A, Albuquerque EX. 2002. The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Mol Pharmacol 61:1222-1234.
32. Schrattenholz A, Pereira EFR, Roth U, Weber KH, Albuquerque EX, Maelicke A. 1996. Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol Pharmacol 49:1-6.
33. Schwartz BL, Hashtroudi S, Herting RL, Handerson H, Deutch SI. 1991. Glycine prodrug facilitates memory retrieval in humans. Neurology 41:1341-1343.
34. Schwartz BL, Hashtroudi S, Herting RL, Schwartz P, Deutsch SI. 1996. D-cycloserine enhances implicit memory in Alzheimer's patients. Neurology 46:420-424.
35. Soderling TR, Derkach VA. 2000. Postsynaptic protein phosphorylation and LTP. Trends Neurosci 23:75-80.
36. Tingley WG, Ehlers MD, Kameyama K, Doherty C, Ptak JB, Riley CT, Huganir RL. 1997. Characterization of protein kinase A and protein kinase C phosphorylation of the N-methyl-D-aspartate receptor NR1 subunit using phosphorylation site-specific sntibodies. J Biol Chem 272:5157-5166.
37. Thomson T, Kewitz H, Bickel V, Straschill M, Holl G. 1991. Preclinical and clinical studies with galantamine. In: Becker R, Giacobini E, editors. Cholinergic Basis of Alzheimer's disease. Boston: Birhauser. pp 328-336.
38. Vidal C, Changeux JP. 1996. Neuronal nicotinic acetylcholine receptors in the brain. News Physiol Sci 11:202-208.
39. Wang YJ, Chen GH, Hu XY, Lu YP, Zhou JN, Liu RY. 2005. The expression of calcium/calmodulin-dependent protein kinase II-α in the hippocampus of patients with Alzheimer's disease and its links with AD-related pathology. Brain Res 1031:101-108.
40. Woodruff-Pak DS, Hinchliffe RM. 1997. Mecamylamine- or scopolamine-induced learning impairment: Ameliorated by nefiracetam. Psychopharmacology 131:130-139.
41. Yamagata Y. 2003. New aspects of neurotransmitter release and exocytosis: Dynamic and differential regulation of synapsin I phosphorylation by acute neuronal excitation in vivo. J Pharmacol Sci 93:22-29.